Former Pharmacyclics CEO raises $75M Series B for new immunotherapy startup Corvus
Corvus Pharma, the brainchild of former Pharmacyclics CEO Richard Miller, just raised a $75 million Series B for its line of checkpoint inhibitor drugs.
Corvus Pharma, the brainchild of former Pharmacyclics CEO Richard Miller, just raised a $75 million Series B for its line of checkpoint inhibitor drugs.
Dr. Patrick Soon-Shiong has two more fundraises under his companies' belt: According to an SEC filing, immuno-oncology startup NantCell has raised $100 million and precision medicine startup NantOmics has raised $150 million.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Bay Area immunotherapy player targets PD-L1 and "Probody" drug conjugates. It'll use the $70 million to advance several candidates into the clinic.
The mysterious company just allocated $75 million to its NantCell division - putting some serious funding behind its precision medicine and cancer immunotherapy efforts.
It has three platforms: A soluble T-cell antigen receptor that zeroes in on cancerous or viral targets; a monoclonal antibody approach using tissue factor antagonists; and an IL-15 platform that's meant to harness IL-15 super-agonists, antagonists and protein scaffolds to build novel immune molecules.
Sweden may not be known for its vibrant medical sector, but healthcare innovation is definitely happening there. As the region’s largest life science partnering conference comes to a close this week, its organizers are calling attention to three young companies they say encompass the strength and innovation in their region. Check out the companies given […]
Cold Genesys, a sort of latter-day spinoff of the once-promising cancer vaccine maker Cell Genesys, has an engineered oncolytic virus that shows promise in treating a dangerous form of bladder cancer. The Newport Beach, California company just received $13.6 million from Hong Kong-based investment fund Ally Bridge Group. It has rejiggered an adenovirus that typically causes […]